Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2022 16:05 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
August 22, 2022 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
August 09, 2022 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
May 04, 2022 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
April 07, 2022 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS)...
March 01, 2022 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
February 28, 2022 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 08, 2021 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
November 03, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 01, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right